-
Fosun Pharma withheld a net profit of 2.2 billion yuan in 2019
Time of Update: 2021-03-06
reporting period, Fosun Pharma achieved operating income of 28.585 billion yuan, an increase of 14.72% over 2018.
In the medical services business, Fosun Pharma achieved operating income of 3.040 billion yuan in 2019, an increase of 18.61 percent over 2018.
-
Three companies have reached a strategic partnership on the type 2 diabetes drug Acapo sugar
Time of Update: 2021-03-06
Wichida, a wholly owned subsidiary of Shanghai Hyundai Pharmaceutical Co., Ltd., will take advantage of the policy dividend of the Drug Listing License Holder (MAH) system, which allows holders to entrust entrusted manufacturers with the production of medicines.
-
Xinlitai, Jingxin, stone medicine performance comparison!
Time of Update: 2021-03-06
Regardless of the focus on monitoring varieties and local medical insurance varieties specifically when to be included in the official agenda, it is clear that the push-out of volume procurement means that the past generic drugs large single high-profit development model gradually ended, and with product clusters, with the advantages of raw material preparation integration enterprises will thicken profits, while forcing enterprises with research and development capabilities to accelerate the transformation to innovation.
-
Policy Year: A group of pharmaceutical companies are sold assets by large companies
Time of Update: 2021-03-06
▍ Large listed companies, sale of assets in small generic pharmaceutical companies through mergers and acquisitions to hold the group heating at the same time, listed pharmaceutical companies because of the size of too large, every decision needs to be handled carefully, more to adjust marketing business, shrink research and development pipeline, reduce costs, sell assets to live capital and other ways.
-
Ophthalmology drug market size of more than 100 billion "lack of medicine and medicine" is still to be solved
Time of Update: 2021-03-06
reporter combed found that at present, including Japan, Novarce, the United States, such as foreign pharmaceutical giants and the rapid rise of domestic ophthalmology drug companies, Kanghong Pharmaceuticals, Sansheng Pharmaceuticals, Xingqi Eye Medicine, Zhuhai Yisheng, etc.
-
Chinese medicine formula particle market "hundreds of flowers in bloom" behind
Time of Update: 2021-03-06
2. Head enterprises began to run away In November last year, the State Pharmacopeia Commission issued the "PublicIty on the Pilot Uniform Standards for Chinese Medicine Formula Particle Varieties", according to which, in accordance with the unified deployment requirements of the State Drug Administration, as of the end of May 2019, it had received a total of 437 studies on 301 varieties submitted by 14 production enterprises and one research institution.
-
By force cdmo gradually become the pharmaceutical enterprises research and development production activities of the optimal solution
Time of Update: 2021-03-06
CDMO's hardware and software capabilities are reflected differently in meeting the core requirements of the two main types of customers of large pharmaceutical companies and innovative small and medium-sized pharmaceutical enterprises.
-
An overview of the development of China's low-value medical supplies industry
Time of Update: 2021-03-06
With the continuous improvement of living standards and the acceleration of the aging process, the number of operations in medical institutions is increasing, china's wound care medical dressing market size in 2018 has exceeded 66 billion yuan.
-
Jingfeng Pharmaceuticals is expected to lose 850 million yuan in 2019
Time of Update: 2021-03-06
2. Sales of major products occurred in the fourth quarter that were not fully expected and did not meet expectations, which had a significant impact on the Company's 2019 operating results the Company's main varieties of ginseng glucose injections failed to enter the august 2019 national health insurance catalogue, and were affected by other relevant policies, sales revenue in the fourth quarter of 2019 decreased by more than 90% compared to the same period in 2018.
-
"Two Big Moves" announced at the same time! Uncover Liaoning into a big capital chess game
Time of Update: 2021-03-06
On the evening of May 8th, Liaoning Chengda Co., Ltd. issued a number of announcements involving two big news: One is a long-rumoured IPO of its controlling subsidiary, Liaoning Chengda Biological C
-
Grapefruit Health has reached an in-depth partnership with bmc Jardine
Time of Update: 2021-03-06
Recently, the domestic pharmaceutical health new retail start-up Grapefruit Health and China's non-invasive ventilator field product and service leader BMC Jardine Jiaye's Remet brand reached in-depth cooperation, the two sides will be through the "professional brand , professional services , physical new retail scene" of the "3 plus" strategy, jointly empower pharmacy terminals, to create domestic sleep apnea, chronic respiratory diseases family health management program.
-
Gree Real Estate entered the medical Fangda Steel proposed to enter the pharmaceutical shares
Time of Update: 2021-03-06
Brand speculation lively, may be just high marketing investment, may not have a real good product.
Fujifilm, on the other hand, has moved into the health industry, using the traditional advantages of film combined with artificial intelligence to establish a brand of medical technology.
-
Shanghai Pharmaceutical Q1 earnings report: revenue, profit double decline to increase research and development investment
Time of Update: 2021-03-06
During the reporting period, Shanghai Pharmaceutical Research and Development Expenses invested 341 million yuan, up 25.93% YoY, and net profit attributable to shareholders of listed companies after reducing research and development expenses, net of non-recurring gains and losses, reached 1.324 billion yuan, up 1.06% YoY.
-
JD.com Launches "Healthy China Medical Grant Project"
Time of Update: 2021-03-06
Under the guidance of the China Association for the Promotion of Poverty Relief Volunteering, relying on the China Social Poverty Reduction Network, the "Healthy China Medical Assistance Project" will accurately identify the identity of the poor people throughout the country and identify the recipients, and JD.com Health will provide 1000 yuan per person per year in drug subsidy funds for the recipients, who can be used when purchasing medicines in the subsidy catalogue through designated channels.
-
Confirm! Ali sells medical devices
Time of Update: 2021-03-06
NO.1 Internet companies entered the medical device May 13, according to enterprise inspection data show that Ali Cloud Computing Co., Ltd. business scope has changed, the addition of the second category of medical device sales.
-
First quarter net profit of Berry Pharmaceuticals increased by 111.07% YoY
Time of Update: 2021-03-06
In addition to the increase in revenue from its main business, technology transfer, service revenue and product equity-sharing revenue also increased significantly in the 2019 annual report released by Boray Pharmaceuticals.
-
Masks and a large number of low-value consumables individuals can purchase directly on the provincial platform
Time of Update: 2021-03-06
individuals can also directly purchase, open online shop sales, but in accordance with the law people can directly purchase on the provincial platform In the procurement model, the news pointed o
-
Tiger Pharma will achieve revenue of 2.8 billion yuan in 2019
Time of Update: 2021-03-06
Tiger Pharma said the increase in revenue from its domestic business during the reporting period was mainly due to an increase in the proportion of in-country innovative pharmaceutical clinical trials.
-
Hengkang Pharmaceuticals is notified of fines for producing and selling inferior drugs
Time of Update: 2021-03-06
On July 5, 2018, the Hubei Provincial Drug Administration issued the "Pharmaceutical Quality Bulletin of Hubei Province (No. 2 of 2018)" showing that two batches of cough Turing capsules (lot number 20170106, 20170309) produced by Jiangxi Hengkang Pharmaceutical Co., Ltd. were detected by the Xiantao City Food and Drug Inspection and Inspection Center as "status" and "moisture" items do not meet the requirements.
-
Demand gap large Huaren pharmaceutical companies began to plan the production of molten spray
Time of Update: 2021-03-06
According to china's industrial textile industry association statistics, as of April this year, the daily production capacity of domestic melt-sprayed non-wovens in about 200 tons (1 ton of molten non-wovens can produce 1 million masks or 300,000 N95 masks).
